CRSP | CRISPR Therapeutics AG Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	47.34 - 51.47
52 Week Range	36.52 - 90.62
Beta	1.56
Implied Volatility	61.54%
IV Rank	46.80%
Day's Volume	2,640,253
Average Volume	2,159,320
Shares Outstanding	85,774,500
Market Cap	4,106,196,864
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-10-19

Valuation
Profitability
Growth
Health
P/E Ratio	-11.03
Forward P/E Ratio	-9.04
EPS	-4.34
1YR Price Target	150.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	407
Country	Switzerland
Website	CRSP

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

CRSP's peers: ARCT, BEAM, BNTX, CRBU, EDIT, VERV, NTLA, FATE, REGN, NVO, SRPT, CWBR, HEPA, RAIN, KRYS, AVRO, PACB, QSI, VRTX, PRME

*Chart delayed

Analyzing fundamentals for CRSP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see CRSP Fundamentals page.

Watching at CRSP technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on CRSP Technicals page.